Dialysis industry news

Stories from the dialysis comunity across the globe.



Factors ID'd for Outcome of Percutaneous Nephrolithotomy - Renal and Urology News PDF Print

Single-tract percutaneous nephrolithotomy (sPCNL) is effective for clearing renal stones, with stone size, location, and prior shockwave lithotripsy (SWL) identified as independent predictors of stone clearance, according to a study published in the July issue of Urology.

Khaled Shahrour, MD, of the University of Toledo Medical Center in Ohio, and colleagues conducted a retrospective review of 351 cases of sPCNL performed by one of two endourologists at a single institution between January 2000 and March 2010. Analyses included preoperative patient and stone factors.

The researchers found that the stone-free rate (SFR) was 76% after either an initial procedure or a second-look nephroscopy. Lower SFR correlated with rising preoperative creatinine, hypertension, increasing stone diameter, complete staghorn stone, presence of stones in the upper pole, and absence of prior SWL, in univariate analysis. In multivariate analysis, stone size, presence of stones in the upper pole, and prior SWL for the active burden remained independent predictors of SFR.

"The purpose of the study is to evaluate the preoperative factors that affect outcome of sPCNL, to aid urologists and patients in making the most appropriate decisions concerning the type of stone treatment," the authors wrote. "Further development of a predictive nomogram of stone clearance and complications is currently being performed."

...

 
Malang kidney patients protest at discontinued regional health scheme - Jakarta Post PDF Print

Kanjuruhan General Hospital: (Courtesy of infokepanjen.com) Kanjuruhan General Hospital:(Courtesy of infokepanjen.com)

Dozens of kidney patients in Malang regency, East Java, stormed the regency administration’s Pendopo(public hall) to protest at the discontinuation of the regional health scheme (Jamkesda) for dialysis treatment.

Patients can no longer have the treatment at Saiful Anwar General Hospital in Malang because the regency administration has not yet reimbursed the costs claimed by the hospital.

“The regency administration does not allow its citizens to be sick. We are very disappointed because hospitals refused us dialysis,” a patient, Yulaikah, said on Friday, as quoted by kompas.com

“Hospitals are worried that the regency will not be able to pay the bills.”

The patients also felt betrayed because in a previous meeting the Malang regency legislative council and the Kanjuruhan General Hospital referred them to Wava Husada and Ben Mari private hospitals, only to be rejected.

“The private hospitals refused to treat us because they were afraid that nobody would pay the bill,” said another patient, Rianti.

Yulaikah said most patients were now suffering from nausea and vomiting because they could not follow the schedules set by their doctors.

The Saiful Anwar General Hospital recommends the patients have dialysis twice a week which costs Rp 750,000 (US$79.74) to Rp 900,000 ($96.30) per visit.

Yulaikah said the patients were now losing hope and were prepared to die. “We no longer trust the government.”

Meawnhile, Malang Regency Health Agency chief Mursyidah refused to comment on the issue, saying the administration’s policy was beyond her power.

“All I can say is that Malang regency citizens should take better care of their health by leading a healthy lifestyle,” she said.

“If residents follow a healthy lifestyle, there will not be so many sick people and the Jamkesda fund will not be depleted so quickly.”

Kanjuruhan General Hospital director, Harry Hartanto, said his hospital only had six dialysis units which could treat 12 patients in batches.

The best solution, Harry said, was for the Saiful Anwar General Hospital to treat patients from Malang regency, adding that the regency administration was still looking for a way to solve the problem. “We ask the patients and their families to be tolerant.” (fzm/nvn)

...

 
Amgen completes KAI Pharmaceuticals takeover - Zenopa PDF Print

Posted on 06/07/2012 in Pharmaceutical Company Restructures

Amgen has finalised its $315 million (202.63 million pounds) acquisition of KAI Pharmaceuticals, as originally announced in April 2012.

KAI Pharmaceuticals is a San Francisco-based healthcare business that is currently developing a lead product candidate called KAI-4169, a treatment for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis.

The drug is designed to be administered intravenously at the same time as the dialysis therapy and has already demonstrated strong promise in phase IIa clinical studies carried out by KAI.

Following the acquisition, Amgen will gain the global rights to commercialise KAI-4169 in all territories excluding Japan, with a loan to be provided in order to support phase III development of the drug.

Commenting on the deal earlier this year, Steve James, president and chief executive officer of KAI, said: "Amgen is ideally positioned to bring KAI-4169 to market and to patients, given the company's decades of experience in developing and delivering therapies for patients with chronic kidney disease."ADNFCR-8000103-ID-801402014-ADNFCR

Other news stories from 06/07/2012

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency

...

 
Dolphy remains critical but stable - ABS CBN News PDF Print

MANILA, Philippines -- King of Comedy Dolphy remains critical but stable as he continues to undergo treatment at the Makati Medical Center (MMC).

"Dolphy's condition remains critical but stable, and his vital organs continue to function well," doctors said in a medical bulletin released by MMC on Friday afternoon.

They added that the Comedy King continues to undergo dialysis sessions and treatment for pneumonia, his twelfth in almost a year.

"Dialysis procedure is being done today, after a very restful day yesterday. Treatment for his pneumonia is also being done, and we are all waiting for results of his response to the treatments," the bulletin read.

Meanwhile, 16 of Dolphy's children are in Manila to be by his side as he remains confined at the MMC's intensive care unit.

“Funny nga, agawan, madami kasi kami. Even Zsa Zsa said every moment now has to be enjoyed. She said that and I was already thinking of that days ago. We are happy,” said Ronnie Quizon, one of Dolphy’s sons.

Despite a prolonged confinement -- he was admitted to the hospital last month -- Dolphy continues to show signs of improvement, according to Quizon.

“There were moments when I said my goodbyes to my dad... everyone had closure but my dad is a fighter. Even the doctor said ‘Fighter talaga si Mang Dolphy,'” he said.

 

...

 
Dialysis Company Pays $55M in Damages - ThirdAge PDF Print

 

Dialysis service provider DaVita Inc. will pay $55 million to settle a lawsuit related to overuse of an anemia medication.

The lawsuit was filed in 2002 and is based on a whistleblower's claim that DaVita overused Epogen, an anemia drug made by Amgen, over a 10-year period.

DaVita says its physicians did nothing wrong and stand by their anemia management practices, but the company says the agreement is in the best interest of its shareholders. In addition to $55 million, the company will pay attorney fees.

Epogen boosts oxygen-carrying red blood cells, reducing the need for painful blood transfusions. However a study in 2009 suggested Epogen and other drugs like it can double the risk of a stroke.

Denver-based DaVita runs about 1,800 outpatient dialysis centers nationwide.

...

 
<< Start < Prev 481 482 483 484 485 486 487 488 489 490 Next > End >>

Page 488 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.